Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
Targa Resources Inc TRGP Bullish Fundamentals Support Prudent Hold Rating Amid Midstream Sector Tailwinds The Walt Disney Co DIS Remains Top Holding In Robert Olsteins Q1 2026 Defensive Value Portfolio Is Magic MEGL stock a safe investment Concorde CIGL Stock Price Target Concorde logs 378 EPS loss on 105T Q1 revenue The Cigna Group CI Jefferies Affirms Buy Rating With Modest Price Target Revision Amid Strategic Community Health Expansion MaxCyte MXCT Stock ShortTerm Trend Technical Strength 20260427 AAUC Allied Gold notches narrow Q4 2025 EPS beat shares post mild gains amid positive investor sentiment How Gemini GEMI is navigating logistics challenges Gemini Misses Estimates Losses Widen Pattern PTRN results smash forecasts with 569 percent EPS beat shares surge 19 percent Weighing Early Social Security Should He Take Benefits at 62 and Invest Kura Oncology KURA Drops 534 Key Support at 876 20260517 Whats Next for NewGenIvf NIVFW at 002 20260518 DeepSeek and Chinas AI Boom Increasingly Powered by State Money Trevi Therapeutics TRVI Q1 2026 Disappoints EPS 009 Below 008 Views China Signals Strong Objection After Trump Remarks on Taiwan Contact 80 of Companies Count Immigrant LeadersTrump Visa Crackdown Spurs Plan C Urgency Immigration Expert Warns Subramanian Swamy Seeks Ban on Cement Imports from Pakistan Over Security Risks COUR Q1 2026 Earnings EPS Misses Estimates but Stock Gains on Positive Outlook Boston Omaha Corporation Q4 2025 Earnings Significant EPS Miss Triggers Stock Decline LZM Q2 2024 Earnings EPS Misses Estimates Shares Rise 876 DAWN Q4 2025 Earnings WiderThanExpected Loss As PreRevenue Biotech Advances Pipeline JXN Q1 2026 Earnings EPS Misses Estimates Amid Market Headwinds Sharps Technology Inc Warrant STSSW Slides 765 as Support and Resistance Converge at 004 Silexion Therapeutics SLXN Slips 3 as Stock Approaches Key Support at 040 Bolt Biotherapeutics BOLT Slips 12 as Shares Test Key Support at 465 Park National Corporation PRK Edges Higher Testing Resistance at 17956